Erasca (ERAS) Corporate presentation summary

Vision and leadership

• Aims to erase cancer in at least 100,000 patients annually as a leading global oncology company.

• Founded by experts in RAS biology, supported by a world-class scientific advisory board with pioneers in RAS/MAPK pathway research.

• Leadership team has a strong track record in drug development and global execution.

Pipeline and scientific differentiation

• Pipeline focuses on shutting down the RAS/MAPK pathway, targeting RAS-mutated and KRAS-mutated solid tumors.

• ERAS-0015 is a pan-RAS molecular glue with best-in-class potential; ERAS-4001 is a pan-KRAS inhibitor with first-in-class potential.

• Both candidates show superior preclinical activity, favorable PK/ADME properties, and robust intellectual property protection through 2043.

Preclinical and clinical data highlights

• ERAS-0015 demonstrates 5–10x greater antitumor activity and higher binding affinity to cyclophilin A compared to RMC-6236.

• Shows potent inhibition across multiple KRAS mutant cell lines and achieves tumor regression at lower doses than competitors.

• ERAS-4001 selectively binds KRAS mutants with high affinity and long residence times, showing potent activity in both GTP- and GDP-bound states.